COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,832 Articles (22,553 medRxiv, 8,279 bioRxiv)

Most recent first Previous |  Page 2917: Articles 29161-29170  | Next

Relevance of enriched expression of SARS-CoV-2 binding receptor ACE2 in gastrointestinal tissue with pathogenesis of digestive symptoms, diabetes-associated mortality, and disease recurrence in COVID-19 patients
Etiologically Elusive Disorders Research Network (EEDRN), , Kumar, A., Faiq, M. A., Pareek, V., Raza, K., Narayan, R. K., Prasoon, P., Kumar, P., Kulandhasamy, M., Kumari, C., Kant, K., Singh, H. N., Qadri, R., Pandey, S. N., Kumar, S.
10.1101/2020.04.14.040204 — Posted: 2020-04-15
Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain
Chi, X., Liu, X., Wang, C., Zhang, X., Ren, L., Jin, Q., Wang, J., Yang, W.
10.1101/2020.04.14.042010 — Posted: 2020-04-15
Genome based Evolutionary study of SARS-CoV-2 towards the Prediction of Epitope Based Chimeric Vaccine
Akhand, M. R. N., Azim, K. F., Hoque, S. F., Moli, M. A., Joy, B. D., Akter, H., Afif, I. K., Ahmed, N., Hasan, M.
10.1101/2020.04.15.036285 — Posted: 2020-04-15
A transcription regulatory network within the ACE2 locus may promote a pro-viral environment for SARS-CoV-2 by modulating expression of host factors.
Fadason, T., Gokuladhas, S., Golovina, E., Ho, D., Farrow, S., Nyaga, D. M., Pan, H., Karnani, N., Wong, C., Cooper, A., Schierding, W., O'Sullivan, J. M.
10.1101/2020.04.14.042002 — Posted: 2020-04-15 Discussion: Onsite
Glycosaminoglycan binding motif at S1/S2 proteolytic cleavage site on spike glycoprotein may facilitate novel coronavirus (SARS-CoV-2) host cell entry
Kim, S. Y., Jin, W., Sood, A., Montgomery, D. W., Grant, O. C., Fuster, M. M., Fu, L., Dordick, J. S., Woods, R. J., Zhang, F., Linhardt, R. J.
10.1101/2020.04.14.041459 — Posted: 2020-04-15 Discussion: Onsite
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
Williamson, B., Feldmann, F., Schwarz, B., Meade-White, K., Porter, D., Schulz, J., van Doremalen, N., Leighton, I., Yinda, C. K., Perez-Perez, L., Okumura, A., Lovaglio, J., Hanley, P., Saturday, G., Bosio, C., Anzick, S., Barbian, K., Chilar, T., Martens, C., Scott, D., Munster, V., de Wit, E.
10.1101/2020.04.15.043166 — Posted: 2020-04-15 Discussion: Onsite | Offsite
Multidrug treatment with nelfinavir and cepharanthine against COVID-19
Ohashi, H., Watashi, K., Saso, W., Shionoya, K., Iwanami, S., Hirokawa, T., Shirai, T., Kanaya, S., Ito, Y., Kim, K. S., Nishioka, K., Ando, S., Ejima, K., Koizumi, Y., Tanaka, T., Aoki, S., Kuramochi, K., Suzuki, T., Maenaka, K., Matano, T., Muramatsu, M., Saijo, M., Aihara, K., Iwami, S., Takeda, M., McKeating, J., Wakita, T.
10.1101/2020.04.14.039925 — Posted: 2020-04-15
TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets
Bestle, D., Heindl, M. R., Limburg, H., Van Lam van, T., Pilgram, O., Moulton, H., Stein, D. A., Hardes, K., Eickmann, M., Dolnik, O., Rohde, C., Becker, S., Klenk, H.-D., Garten, W., Steinmetzer, T., Bottcher-Friebertshauser, E.
10.1101/2020.04.15.042085 — Posted: 2020-04-15 Discussion: Offsite
Analysis of SARS-CoV-2-controlled autophagy reveals spermidine, MK-2206, and niclosamide as putative antiviral therapeutics
Gassen, N. C., Papies, J., Bajaj, T., Dethloff, F., Emanuel, J., Weckmann, K., Heinz, D. E., Heinemann, N., Lennarz, M., Richter, A., Niemeyer, D., Corman, V. M., Giavalisco, P., Drosten, C., Muller, M. A.
10.1101/2020.04.15.997254 — Posted: 2020-04-15 Discussion: Onsite | Offsite
Genetic Variability of Human Angiotensin-Converting Enzyme 2 (hACE2) Among Various Ethnic Populations
Li, Q., Cao, Z., Rahman, P.
10.1101/2020.04.14.041434 — Posted: 2020-04-15

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).